Pathology: mHCC - (neo)adjuvant (NA); mHCC - 1st line (L1);
mHCC - (neo)adjuvant (NA) | mHCC - 1st line (L1) | |||
IMbrave050, 2023 | IMbrave-150, 2020 | COSMIC-312, 2023 | ||
atezolizumab plus bevacizumab | 2 | T1 | T1 | |
atezolizumab plus cabozantinib | 1 | T1 | ||
Standard of Care (SoC) | 0 | T0 | ||
sorafenib | 0 | T0 | T0 |